Director, Gene and Cell Therapy
Sarcoma Oncology Research Center
Santa Monica, California, United States
Dr. Gordon is a practicing medical oncologist and serves as Director of Gene and Cell Therapy/Immunotherapy and Chairman of the Institutional Biosafety Committee at the Cancer Center of Southern California/Sarcoma Oncology Research Center, an academic medical institution that conducts ~15 active pharma-sponsored and investigator initiated/sponsored clinical trials for cancer. She is principal investigator of 5 clinical studies and sub-investigator of 15 industry sponsored and Investigator Sponsored Trials (ISTs) for sarcoma and other solid tumors. She served as Editor-in Chief of the International Pediatric Hematology/Oncology Journal (1995-2001), Guest Editor of Cancers and Frontiers in Molecular Medicine (2022), and is an active member of the American Society of Clinical Oncology, European Society of Medical Oncology, Society of Immunotherapy for Cancer, American Association for Clinical Research, Connective Tissue Oncology Society, etc.
Leading the field of genetic medicine forward, Dr. Gordon licensed the first academic Viral Vector Production Facility in the world in 1994, served as its first Medical Director, and, together with Dr. Frederick Hall, has developed an extensive intellectual property portfolio (>200 patents/patent applications) on targeted gene delivery for cancer, COVID-19 and other proliferative disorders. Dr. Gordon has published over 100 peer-reviewed articles and book chapters. Dr. Gordon was recipient of a Research Career Development Award from the United States NIH from 1985-90, multiple awards from the United States Local and National American Heart Association from 1982-2001, RO1 research award from the USFDA from 2006-2008, an Award for Excellence in Biotechnology from the City of Los Angeles, CA in 2004, the Thomas Award for Medical Research from the UST Medical Alumni Association in 2016 and 2021.
Disclosure information not submitted.
